Covid-19 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Second wave of late-phase Covid-19 vaccine trials unlikely to require a higher efficacy bar for FDA authorisation

The FDA is likely to face pressure to raise the efficacy bar for an authorization if there are one or two Covid-19 vaccines with an EUA. Credit: Shutterstock.